How can biopharma deliver on the promise of precision medicine?

Biopharma and biotech companies require access to high quality, deeply curated patient data to scale precision medicine initiatives. While vast amounts of clinical and genomic data are available in various forms, they are not effectively leveraged to understand disease and wellness. To span this divide, advanced data engineering and data science approaches are needed. That said, the launch of a precision medicine does not automatically guarantee the delivery to the right patient at the right time. To make it standard of care, therefore, the answer lies in the “how”.

Join this webinar presented by Sema4, a patient-centered health intelligence company, where expert panelists will discuss the barriers to bring precision medicine to the patient and possible ways to overcome them.

Attendees can expect to learn about:
  • The role of deep, longitudinal clinical and multi-omic datasets in advancing precision medicine initiatives
  • The role of advanced bioinformatics and systems biology in uncovering differentiated insights across the entire drug development lifecycle
  • The role of educating clinicians and patients to optimize delivery of precision medicine at scale and to measure its impact
Roles that will benefit the most from this webinar are those with responsibilities for:
  • Precision Medicine/Translation Medicine
  • RWD/RWE/Advanced Analytics
  • Diagnostics/Biomarkers
  • Bioinformatics/System Biology
  • Data Scientists
  • Clinical Development
  • Clinical Operations
  • Global Medical Affairs
watch now
Watch the webinar on demand
Maria Karasarides

Maria Karasarides

Vice President of Early Assets & Biomarkers, Worldwide Medical Oncology, Bristol Myers Squibb

Vice President of Early Assets & Biomarkers, Worldwide Medical Oncology, Bristol Myers Squibb Maria Karasarides, Ph.D. is the Vice President of Early Assets & Biomarkers in Worldwide Medical Oncology at Bristol Meyers Squibb. She oversees medical strategy and innovation to accelerate the application of early development into clinical practice. Her experience spans academic & pharmaceutical development with a focus on clinical, translational research, and medical affairs. She held leadership positions at Regeneron Pharmaceuticals, Astra Zeneca and Bristol Myers Squibb where she advanced the development of investigational immune modulating therapies, durvalumab (ImfinziTM) & tremelimumab based combinations, and was a key member of the ipilimumab (Yervoy®) launch team. Dr. Karasarides holds a Ph.D. in biology/biochemistry and conducted her graduate work on RAS/PI3K signaling at the Lerner Research Institute, Cleveland Clinical Foundation. During her post-doctoral fellowship at the Institute of Cancer Research, London, UK, she delineated BRAF as a therapeutic target in melanoma.

Sean Khozin

Sean Khozin

Chief Executive Officer, CancerLinQ LLC and Executive Vice President, ASCO

Dr. Khozin, MD, MPH, has more than a decade of leadership experience in health technology, regulation, clinical research, and data science, including the application of AI and ML in biomedical research, therapeutic development, and care delivery. He was previously the Global Head of Data Strategy and Data Science Innovation at Janssen R&D of Johnson & Johnson, managing a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative medicines. He led the FDA Oncology Center of Excellence’s bioinformatics, regulatory science, and clinical trial innovation efforts. He was also the founding Executive Director of Information Exchange and Data Transformation, FDA’s first data science and technology incubator. He received his Master of Public Health degree from George Washington University, and Doctor of Medicine degree from University of Maryland School of Medicine. He is a board-certified oncologist.

Michelle Zimmerman

Michelle Zimmerman

Chief Strategy & Transformation Officer, Sema4

Michelle is a seasoned healthcare executive with expertise building and growing companies in digital health, health services, health insurance, and health information. In her current role, she is responsible for incubating new lines of business that leverage Centrellis® platform to transform standard of care across new areas of disease and wellness. She oversees corporate strategy, the strategic planning process, and defines corporate development priorities to advance Sema4’s mission. She also serves as the SVP and GM of Oncology Solutions, leading the oncology BU and scaling data-driven solutions to enable precision cancer care. She has served as SVP, U.S. Operations & Business Development for Mavencare, a venture-backed home health company, and as Chief Innovation Officer at AlphaCare, a managed care plan acquired by Magellan Health. She began her career in management consulting with Boston Consulting Group and then in corporate law with Paul Weiss, Rifkind, Wharton & Garrison.

William K. Oh

William K. Oh

Chief Medical Science Officer, Sema4

Dr. Oh, MD, is an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. He is responsible for strategy development, scientific collaborations, clinical development programs, and adoption of Sema4’s health intelligence offerings in oncology and a broad spectrum of human diseases. William has served as Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute. He was also the Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School. He was the founding Chair of Data and Safety Monitoring Committee for Phase I/II Trials at the Harvard Cancer Center. William continues to care for his patients as Clinical Professor of Medicine at Icahn School of Medicine.